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Aim 
To develop a non-invasive, safe and reproducible target-engagement biomarker for future 
TRPA1 antagonists in healthy volunteers. 
 
Methods 
Dose Finding (n=11): 3%, 10%, and 30% cinnamaldehyde (CA) and placebo (=vehicle) was 
topically applied on the right forearm. One-way ANOVA with post-hoc Bonferroni was used 
to compare between doses. Reproducibility: 10% CA doses were topically applied during 1 
visit on both arms (n=10) or during 2 visits (n=23) separated by a washout period of 7 days. 
CA-induced dermal blood flow (DBF) was assessed by laser Doppler imaging (LDI) at 
baseline and at 10, 20, 30, 40 and 50 minutes post-CA. Paired T-test was used to compare 
between arms or visits. Concordance correlation coefficient (CCC) was calculated to assess 
reproducibility. Data are expressed as percent change from baseline (mean±95% CI). 
 
Results 
All 3 doses increased DBF compared to vehicle at all time-points, with the maximum 
response at 10-20 min post-CA. Dose response was found when comparing AUC0-50min of 
30% CA (51,364±8,475%*min) with 10% CA (32,239±8,034%*min, p=0.03) and 3% CA 
(30,226±11,958%*min, p=0.015). 10% CA was chosen as an effective and safe dose. DBF 
response to 10% CA was found to be reproducible between arms (AUC0-50min, CCC=0.91) 
and visits (AUC0-50min, CCC=0.83). Based on sample size calculations, this model allows to 
detect a change in CA-induced DBF of 30-50% between 2 independent groups of maximum 
10-15 subjects with 80% power. 
 
Conclusion  
Evaluation of cinnamaldehyde induced changes in DBF offers a safe, non-invasive and 
reproducible target-engagement biomarker in vivo in humans to evaluate TRPA1 
antagonists. 
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What is known about this subject?  
 Cinnamaldehyde, the main component of cinnamon, activates the TRPA1 receptor 
and induces vasodilatation when applied on the human skin. 
 TRPA1, a non-selective cation channel, is expressed in small diameter nociceptors 
and involved in persistent to chronic painful states such as inflammation, neuropathic 
pain and migraine. 
 TRPA1 is an emerging target for treating these and other neurogenic inflammatory 
conditions.  
 
What this study adds?  
 Cinnamaldehyde 10% topical solution is tolerable and safe to use in healthy 
volunteers. 
 Cinnamaldehyde 10% applied on the human skin induces a robust increase in 
dermal blood flow which can be measured with Laser Doppler imaging and is 
reproducible over time and between arms.  
 The cinnamaldehyde model can be used in future early clinical development studies 
with TRPA1 antagonists as a target engagement biomarker to guide dose selections 
for efficacy studies.  
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Introduction 
Cinnamaldehyde (CA), the main component of Cinnamoni Cortex, is commonly used for 
flavoring and fragrance in foods, cosmetics and as a herbal medicinal product to treat 
infections, arthritis, and cardiovascular diseases [1-3]. Cinnamaldehyde activates the 
transient receptor potential ankyrin type 1 receptor (TRPA1), a non-selective cation channel 
that belongs to the Transient Receptor Potential (TRP) superfamily. Transient receptor 
potential channels (TRP channels) are a group of ion channels that are ubiquitously 
expressed in many cell types and tissues, both neuronal and non-neuronal. TRPA1 is often 
co-expressed with the transient receptor potential vanilloid type 1 receptor (TRPV1) in small 
to medium-diameter nociceptors of the dorsal root, trigeminal, jugular and nodose ganglia.As 
a result, they co-localize with peptidergic markers such as calcitonin gene-related peptide 
(CGRP), prostaglandins (PGs) and substance P (SP) [4-7]. Consequently, activation of 
TRPA1 by CA results in the release of these inflammatory mediators and neuropeptides 
which, in turn, impact surrounding tissues including: mast cells, immune cells and vascular 
smooth muscle cells. The resulting response encompasses redness and warmth due to 
vasodilatation and hypersensitivity due to excitation of primary sensory neurons; a response 
which is commonly referred to as “neurogenic inflammation” [8, 9]. This makes TRPA1 a 
promising target for anti-inflammatory and analgesics drugs for example for the treatment of 
migraine [10, 11].  Interestingly, TRPA1 is also expressed in non-neural cells of the human 
skin and involved in keratinocyte differentiation and dermal inflammatory responses [12, 13].  
Preclinically, it has been shown that CA injection causes an increase in blood flow in the skin 
of anesthetized WT mice but not in TRPA1 KO mice [14]. Likewise, the topical application of 
CA caused a TRPA1-dependent acute inflammatory response characterized by edema 
formation and leukocyte infiltration [15]. Aubdool et al. showed that CGRP plays a key role in 
this murine TRPA1 activation, but also neuronal nitric oxide synthase (nNOS) derived nitric 
oxide (NO) is involved [16]. The first human data were reported by Namer et al. who 
demonstrated that the topical application of 10% CA on the forearm of healthy volunteers 
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elicited a burning pain sensation as well as heat and mechanical hyperalgesia [17, 18]. 
Additionally, an exploratory study in human volunteers showed that the topical application of 
1% CA to the forearm caused intense local cutaneous erythema and vasodilatation 
accompanied by a selective and dose-dependent release of PGD2 at the site of application 
[19].  
Taken together, these findings indicate the potential of TRPA1 as a target for persistent to 
chronic painful states such as inflammation, neuropathic pain and migraine [14]. However, 
the transition between preclinical and clinical development is likely the biggest hurdle in the 
development of novel analgesics. The use of target engagement biomarkers can potentially 
reduce this hurdle by measuring the interaction between the investigational medicinal 
product and the claimed target in the human body [20]. For example, the capsaicin model, 
developed for the activation of TRPV1 and release of CGRP, has been used extensively to 
guide dosing decisions in the early clinical development of TRPV1 antagonists and 
therapeutics interfering with CGRP or CGRP-receptors [21].  
The aim of this study was to develop a non-invasive, safe and reproducible target-
engagement biomarker for future TRPA1 antagonists. To that end, cinnamaldehyde (CA) 
induced dermal blood flow was evaluated using laser Doppler imaging (LDI) in healthy 
volunteers. 
 
Methods 
Subjects 
Approval was obtained from the Ethics Committee of the University Hospitals Gasthuisberg, 
Leuven, Belgium (S54787/ML8725). All study procedures were carried out in accordance 
with the Declaration of Helsinki, 2013. Subjects were recruited via an approved database 
available at the Centre for Clinical Pharmacology. Written informed consent was obtained 
from all subjects prior to screening. All subjects were healthy (based on medical history), 
Caucasian, non-smoking volunteers between the age of 18 and 45 years. They could not 
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have any skin disorders, excessive forearm hair growth, or allergies to any of the 
investigational products used and were not taking any medication throughout the duration of 
the study.  
Subjects were told to refrain from alcohol and caffeine consumption, to avoid use of topical 
treatments or lotions on the forearm 12 hours prior to each study visit and to fast 3 hours 
prior to each study visit. 
 
Study design 
Dose-response testing included 1 study visit during which 3 different doses of CA (3%, 10% 
and 30%) and vehicle were applied on the right forearm. Doses were based on the 
preclinical experiments of Aubdool et al. [16] and the clinical study of Namer et al. [17]. Inter-
arm reproducibility testing included 1 study visit during which 1 dose of 10% CA and 1 dose 
of vehicle was applied on the left and right arms. Inter-period reproducibility testing included 
2 study visits; during each visit 1 dose of 10% CA and 1 dose of vehicle was applied on the 
right forearm. Visits were separated by a wash-out period of at least 7 days. Visit were 
randomly planned in the morning or afternoon.  
During each study visit, subjects rested in a semi-recumbent position on a comfortable bed 
in a quiet, temperature controlled room (23°C ±1°C) where all measurements were 
performed. Subjects underwent 30 minutes of acclimatization during which study restrictions 
were checked and blood pressure and heart rate measurements (Omron®, Model M6, 
Digital automatic blood pressure monitor, Intellisense TM) were performed.  
After acclimatization, O-shaped rubber rings (10mm diameter, Quad Ring BS011 NBR 70 
Shore A; Polymax Ltd) were placed on the volar surface of the forearm at equidistance sites 
and away from visible veins (4 rings on the right arm for dose-finding, 2 rings on both the 
right and left arm for inter-arm reproducibility and 2 rings on the right arm for inter-period 
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reproducibility). The rubber O-rings served as reservoirs for the topical application of 20μL of 
CA or vehicle; the O-rings were not attached to the skin to avoid adverse local skin 
reactions. The rings were always placed within the same 4x4 cm zones on the forearm with 
1 cm between zones and the first zone starting 5 cm distal from the elbow. The forearms of 
the subjects were placed in U-shaped cushions to prevent movement. DBF was measured at 
baseline (i.e. prior to CA/vehicle application) and at 10, 20, 30, 40 and 50 minutes after 
CA/vehicle application, using Laser Doppler Imaging (LDI) (PIMII, Perimed®). The pain 
intensity induced by CA application was assessed using the numerical rating scale -11 
(NRS-11) before each LDI scan. Subjects were asked to score their pain orally on a numeric 
scale from 0 to 10, where 0 means “no pain at all” and 10 means “the worst pain you can 
imagine”.  
 
Cinnamaldehyde 
CA 99% was obtained from Sigma-Aldrich N.V. (Bornem, Belgium) and dissolved in a 3:3:1 
mixture of ethanol 100%, Tween -20, and distilled water to obtain 3%, 10% and 30% CA 
concentrations. The vehicle solution corresponded to the same 3:3:1 mixture of ethanol 
100%, Tween -20, and distilled water without CA.  
 
Statistics 
For dose-finding, the mean DBF response within the area of the rubber O-ring of the right 
arm was measured at each time point for 3%, 10%, and 30% CA and vehicle. The DBF 
response was expressed as mean percent change from baseline ± 95% confidence interval 
(95% CI); the corresponding area under the curve up to 50 minutes after CA application 
(AUC0-50min) was calculated as a summary measurement. One-way analysis of variance 
(ANOVA) with post-hoc Bonferroni correction was used to test for significant difference 
between doses. P-value <0.05 was considered as significant. 
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For reproducibility, the mean DBF response within the area of the rubber O-ring at each time 
point for both arms and periods was measured for 10% CA and vehicle. DBF response was 
expressed as mean percent change from baseline ± 95% confidence interval (95% CI) and 
the corresponding AUC0-50min was calculated as a summary measurement. For each subject, 
the DBF response was compared between the left and right arm for inter-arm reproducibility 
and between visit 1 and visit 2 for inter-period reproducibility using paired T-test for normally 
distributed data and related-samples Wilcoxon signed rank test for non-normally distributed 
data. Shapiro-Wilk Test was used to assess the normality of the data distribution. P-value 
<0.05 was considered as significant. Significant outliers were excluded using Cook’s 
distance before proceeding with the reproducibility tests.  
Test-retest reproducibility was further assessed using the mean difference, the concordance 
correlation coefficient (CCC), Bland-Altman graphs and the Bradley-Blackwood tests. The 
CCC assesses both accuracy and precision; a value closer to 1 indicates a more 
reproducible response.  Bland-Altman plots were created to assess the agreement of the 
individual mean DBF responses between arms or visits (pairwise means) versus the 
difference in individual DBF responses between arms or visits (pairwise difference). The 
corresponding Bradley-Blackwood test gives an estimate whether the regression coefficients 
in the regression of the pairwise difference versus the pairwise means are significantly 
different from 0 [22]. Sample size calculations (SSC) for independent samples T-test with 
continuous response measures were performed using PS: Power and Sample Size 
Calculator® software. Sample sizes required to detect a predetermined difference of 10, 20, 
30, and 50% in DBF response given a significance level of 5% and a power of 80% were 
calculated. The active/vehicle ratio was assumed to be 1.  
Drug/molecular target nomenclature is based on the BJP’s Concise Guide to 
PHARMACOLOGY 2015/16 [23]. 
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Results 
SAFETY 
Topical applications of 3% and 10% of CA on the forearm were well tolerated by all subjects. 
With the 30% CA dose, a mild and transient dermatitis reaction was reported in 2 subjects. 
In most subjects, 10 and 30% CA provoked a very mild itching sensation about 10 minutes 
post-application. This itching sensation disappeared within 20-30 minutes. Subjects gave 
NRS-11 scores ranging from 0-5 after 10 and 20 minutes and all scores were 0 at the 
subsequent time points for all CA and vehicle doses. No significant differences were found 
between NRS-scores for CA 3% (1.2±1.0; 0.18±0.6), 10% (1.2±1.0; 0.2±0.6), 30% (1.2±1.0; 
0.3±0.7) or vehicle (0.6±1.1; 0±0) at 10 or 20 minutes, respectively (p=0.893; p=0.591; 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons). All three doses of CA 
elicited a transient local redness at the site of application, which disappeared within hours 
after completion of the measurements. Based on these data, 3% and 10% CA were 
considered safe to use in humans.  
 
EFFICACY 
Dose finding  
Dose finding experiments were performed in a total of 11 healthy Caucasian volunteers, of 
which 9 were male. Mean ± SD (range) for age, body mass index (BMI), systolic blood 
pressure, diastolic blood pressure and heart rate were: 26 ± 3 (22-33) years, 22 ± 3 (17-26) 
kg/m2, 118 ± 9 (104-132) mmHg, 71 ± 6 (60-73) mmHg and 67 ± 7 (57-81) bpm, 
respectively.  
 
An increase in DBF (expressed as % change from baseline ± 95% CI) was observed for all 
three doses of CA, starting from 10 minutes post-CA application and gradually declining 
thereafter (Figure 1A). The increase in DBF was different from vehicle for all 3 doses at all 
30 40 
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time points (p<0.001, one-way ANOVA with Bonferroni correction for multiple testing). The 
maximum DBF was observed at 10 minutes after 30% CA (1,292 ± 229 %); at 20 minutes 
after 10% CA (1,042 ± 238%) and 3% CA (938 ± 354%) application. For all doses, the DBF 
response was slowly returning to baseline at 50 min post-dose. However, no LDI 
measurements were done after this time point. Based on visual inspection of the forearms 
the increased DBF was back to baseline after approximately 60 min. The most robust DBF 
response was induced by the 30% CA dose. The DBF response induced by 30% CA was 
significantly different from that of 3% CA at all time points: 1,292 ± 229 versus 864 ± 375% 
at 10 min (p=0.01), 1,265 ± 228 versus 938 ± 354% at 20 min (p=0.04), 1,197 ± 189 versus 
867 ± 332% at 30 min (p=0.02), 1,046 ± 195 versus 724 ± 323% at 40 min (p=0.01) and 708 
± 163 versus 518 ± 279% at 50 min (p=0.04) (One-way ANOVA with post-hoc Bonferroni). 
No significant difference was observed between the DBF response induced by 30% CA and 
10% CA or between 10% CA and 3% CA at any of the time points.  
When the DBF response was expressed as area under the curve from 0 to 50 minutes 
(AUC0-50min, %change from baseline*min), the DBF induced by 30% CA (51,364 ± 
8,475%*min) was higher than that of 10% CA (32,239 ± 8,034%*min, p=0.02) and 3% CA 
(30,226 ± 11,958%*min, p<0.008) (Figure 1B). AUC0-50min was higher compared to vehicle 
(616 ± 205%*min) for all doses (p<0.001) There was no significant difference between the 
DBF (AUC) response between the 10% and 3% CA (p>0.05) (one-way ANOVA with post-
hoc Bonferroni). 
The same results were found when analyzing the DBF in the flare region (=outside the 
rubber O-ring) (Suppl. Fig. 2) 
Because 30% CA caused local dermatitis in 2 subjects and 3% CA showed larger inter-
subject variability, the 10% CA dose was chosen as a safe and efficacious dose to further 
develop the model as a biomarker and to investigate the reproducibility. 
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Intra-subject Inter-period and inter-arm reproducibility  
The inter-arm reproducibility (Figure 2B) was completed in 10 healthy Caucasian 
volunteers, of which 6 were males. Mean ± SD (range) for age, body mass index (BMI), 
systolic blood pressure, diastolic blood pressure and heart rate were 23 ± 2 (19-25) years, 
21 ± 3 (19-25) kg/m2, 119 ± 13 (99-138) mmHg, 73 ± 7 (63-82) mmHg and 76 ± 9 (63-93) 
bpm, respectively.  
There was no difference in DBF response to 10% CA between the right and left arm at 10 
minutes (1,087 ± 372 versus 1,009 ± 349%, p=0.60), 20 minutes (1,181 ± 405 versus 1,236 
± 363%, p=0.80), 30 minutes (1,084 ± 401 versus 1,135 ± 365%, p=0.91), 40 minutes (921 ± 
418 versus 992 ± 414%, p=0.44), and 50 minutes (642 ± 356 versus 686 ± 346%, p=0.26) 
(paired T-test). The maximum DBF response was observed at 20 minutes in both the right 
(1,181 ± 405%) and left arm (1,236 ± 363%) (Figure 2A). The CCC was >0.8 (= substantial-
almost perfect) for all time points except at 10 min post-CA (CCC=0.74, moderate) (Table 1). 
Vehicle did not induce a DBF response at any of the time points and was identical between 
the right and left arm (p>0.05, paired T-test). AUC0-50min of the CA-induced DBF did not differ 
between the arms (38,127± 13,696 versus 38,771 ± 11,946%*min, p=0.80, paired T-test). 
Based on CCC (0.91) and Bradley-Blackwood test (p=0.30), AUC0-50min was found to be 
reproducible between arms. 
Sample size calculations learned that the CA model is able to detect a change of 30-50% in 
DBF between 2 independent groups with a maximum of 10 subjects when comparing 
between arms (Table 2).  
 
The inter-period reproducibility (Figure 2A) was completed in 25 healthy Caucasian 
volunteers, of which 13 were males. Mean ± SD (range) for age, body mass index (BMI), 
systolic blood pressure, diastolic blood pressure and heart rate were 24 ± 5 (19-46) years, 
22 ± 3 (17-25) kg/m2, 117 ± 10 (99-138) mmHg, 72 ± 7 (60-82) mmHg, 72 ± 11 (50-93) bpm, 
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respectively. As 2 outliers (1 male, 1 female) were eliminated from further statistical tests 
based on Cook’s distance test, in the final inter-period reproducibility analysis 23 subjects 
were included. 
There was no difference in the CA-induced DBF response between visit 1 and visit 2 after 10 
minutes (907 ± 189 versus 966 ± 181%, p=0.69), 20 minutes (1,091 ± 194 versus 1,099 ± 
245%, p=0.10), 30 minutes (1,000 ± 205 versus 1,048 ± 290%, p=0.31), 40 minutes (808 ± 
214 versus 778 ± 226%, p=0.22), and 50 minutes (480 ± 161 versus 484 ± 181%, p=0.59) 
(paired T-test). The maximum DBF response was observed at 20 minutes in both visit 1 
(1,091 ± 194%) and visit 2 (1,099 ± 245%). The CCC varied from 0.65 to 0.8 (= moderate) at 
20 and 50 min post-CA, CCC was below 0.65 (=poor) at 10, 30 and 40 min post-CA (Table 
1). Vehicle did not induce a DBF response at any of the time points and was identical 
between visit 1 and 2 (p>0.05, paired T-test). AUC0-50min of the CA-induced DBF was not 
different between visit 1 and 2 (24,988± 4,490 versus 25,836 ± 5,285%*min, p=0.568, paired 
T-test). Based on CCC (0.83) and Bradley-Blackwood test (p=0.18), AUC0-50min was found to 
be reproducible between visits. 
Sample size calculations learned that the CA model is able to detect a change of 30-50% in 
DBF between 2 independent groups with a maximum of 15 subjects when comparing 
between visits (Table 2).  
Additional reproducibility analysis and sample size calculations are shown in table 1 and 2. 
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Discussion 
The use of cinnamaldehyde-induced changes in dermal blood flow is presented as a safe, 
non-invasive and reproducible target-engagement biomarker to test future TRPA1 
antagonists.  
First, in the dose finding part of this study it was shown that all 3 doses of CA increased DBF 
compared to vehicle at all time-points, with the maximum response at 10-20 min post-CA 
application. A difference in dermal blood flow response was found when comparing AUC0-
50min of 30% CA with 10% CA and 3% CA. At all time points measured (10-50 min post 
cinnamaldehyde application), a difference was found between 30% CA and 3% CA. No 
difference was found between 10% and 3% CA which is likely due to the high inter-subject 
variability of the 3% dose. Thirty percent (30%) CA caused a transient dermatitis at the site 
of application in 2 volunteers, whereas, 3% and 10% CA caused limited to no irritation. NRS-
11 pain scores were less than 5 in all subjects. Hence, 10% CA was the most optimal and 
safest dose to continue with, as it produces a robust DBF response with low inter-individual 
variability as well as minimal skin irritation. These findings seem to be in line with the study 
of Namer et al. where also 10% CA was used, however, they expressed  DBF as area of 
vasodilatation and not as perfusion units.  
Second, in the reproducibility part of this study, the DBF response to 10% CA was found to 
be reproducible between arms as well as between visits. Reproducibility between arms was 
better compared to inter-period reproducibility. This slightly lower inter-period reproducibility 
may be attributed to the diurnal variation in forearm blood flow, which has been shown to be 
lower in the morning and increased by 58% during the day [24]. Several mechanisms may 
explain the circadian pattern of forearm blood flow, including increased α-sympathetic 
vasoconstrictor activity in the morning, which affects the vasculature tone. Skin temperature 
has also been shown to be associated with dermal blood flow, and skin temperatures are 
slightly lower in the mornings. As a result, there is a lower metabolic rate in the early hours 
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and thus less demand of nutrients to be delivered via the blood flow. In our study, the LDI 
measurements for each subject were not necessarily made at the same time of the day in 
visit 1 and visit 2, which may have led to a slight difference in DBF response and increased 
variability. To minimize the influence of skin temperature, measurements were always 
performed at a standardized temperature (23°C ± 1°C) and after sufficient acclimatization.  
Regarding the reproducibility calculations, CCC and Bradley Blackwood in combination with 
paired t-tests were chosen as preferred parameters, as recommended by Russel et al. [25].  
The Bradley-blackwood test is easy to implement and corresponds with the graphical 
methods of Altman and Bland [26]. CCC is a reliable measure of reproducibility that 
measures the agreement between two variables by assessing the degree to which pairs of 
observations fall on the 45º line through the origin. It is essentially a modified version of the 
Pearson coefficient of correlation, which measures how close the data points fall relative to 
the line of best fit. CCC is superior in the sense that it takes into account how far the line of 
best fit lies from the 45º line through the origin [27].  
Based on these reproducibility calculations, we were able to calculate the sample size, which 
showed that the CA model is able to detect a change of 30-50% between 2 independent 
groups of 15 subjects with 80% power. However, it is important to keep in mind that every 
model is only a surrogate of reality and has its limitations. Because TRPA1 antagonists are 
not yet available for human use, we were not able to test the specificity of the response to 
CA for TRPA1 in humans. However, extensive preclinical experiments support this specificity 
and currently, no evidence for species differences in CA sensitivity has been reported [8, 28, 
29]. In line with other DBF models such as the capsaicin model, one can assume that 
several factors such as sex, age and body site can play a role in the response to CA. Our 
sample of healthy subjects consisted of males and females within a predefined age range. 
Interestingly, no significant difference was found between males and females (suppl. Fig. 1), 
although, at 20 min, there seems to be a trend (unpaired T-test, p=0.12) towards a higher 
response in women. However, this is probably due to a small, non-significant difference in 
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baseline DBF (32 PU (females) vs 45 PU (males), p=0.4, unpaired T-test)  Only the volar 
surface of the forearm was used for application of CA so as a consequence, our model only 
represents peripheral activation of TRPA1 which can most obviously be used to investigate 
TRPA1 related peripheral disorders. In the context of migraine, where trigeminal activation of 
TRPA1 is hypothesized to play an important role, it would also be interesting to evaluate the 
application of CA on the skin of the forehead in order to activate trigeminal TRPA1 channels. 
If central rather than peripheral activation of TRPA1 channels is involved in migraine, the 
added value of CA-induced changes in DBF as a biomarker for target engagement could be 
questioned. However, also in that case, CA-induced changes in DBF as a biomarker could 
still provide very useful information to guide dose selection for efficacy studies.  
Unlike other non-invasive DBF models such as the capsaicin model, no non-responders (i.e. 
DBF increase of <100% compared to baseline) were reported with the 10% CA-model. This 
gives the CA model an extra advantage as a target-engagement model in future clinical 
research. Moreover, there seems to be no desensitization of the CA-response after repeated 
administration, which is in line with preclinical findings in mice [15]. Another unresolved 
question is whether the DBF response observed is due to activation of neuronal and / or 
vascular TRPA1. Based on preclinical findings of Aubdool et al., it seems that neuronal 
TRPA1 is activated which in turn causes the release of several neuropeptides including 
CGRP, Substance P and prostaglandins and are most likely to play an important role in the 
neurogenic inflammation reaction [8, 28, 29]. Therefore, future research questions still to be 
looked into are: (1) which second messengers are involved in the DBF response after CA 
application in vivo in humans and (2) what is the influence of TRPV1 co-activation. Additional 
topics for further investigation are potential differences in the response to CA between 
different populations (e.g. migraine patients) and possible within subject differences in 
response to CA depending on the area of application. As there is growing evidence that 
targeting TRPA1-mediated neurogenic inflammation of the trigeminal system might be 
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beneficial in migraine [10, 11], this non-invasive model will be useful for testing novel anti-
migraine and analgesic drugs linked with TRPA1 and CGRP. 
Taken together, we have developed a target engagement biomarker to test TRPA1 
antagonists in vivo in humans that is non-invasive, reproducible and safe. The model 
provides an objective pharmacodynamics endpoint which is easy to incorporate in phase I 
clinical trials. The use of this model in exploratory clinical trials with TRPA1 antagonists 
and/or related mediators is an extra asset to facilitate dose-selection and go/no go decisions 
in early clinical drug development.  
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Table 1 Test-Retest Reproducibility of Dermal Blood Flow Response induced by 10% CA based on CCC and BB-test. 
Time 
Inter-Arm 
Reproducibility 
(n=10) 
Inter-Period 
Reproducibility 
(n=23)  
CCC 
BB-
test* 
CCC 
BB-
test* 
10 min 0.74 0.7921 0.62 0.5965 
20 min 0.84 0.5694 0.73 0.0886 
30 min 0.95 0.3355 0.45 0.0664 
40 min 0.99 0.8500 0.55 0.8112 
50 min 0.99 0.5808 0.74 0.4362 
 
Test-retest inter-period and inter-arm reproducibility for DBF response expressed as percentage change in baseline at 10, 20, 30, 40 and 50 minutes after CA application. 
CCC: concordance correlation coefficient 
CCC>0.9, almost perfect; CCC 0.8-0.9, substantial; CCC 0.65-0.8, moderate; CCC<0.65, poor 
*Bradley-Blackwood Test: p<0.05 indicates evidence of unequal means or unequal variances between period 1 and period 2 or between right arm and left arm. 
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Table 2 Sample Size Calculations for Dermal Blood Flow Response induced by 10% CA 
DBF 
response 
Test-
Retest 
Mean 
Difference (95% 
CI) 
CCC 
SSC 
10% 
shift 
SSC 
30% 
shift 
SSC 
50% 
shift 
Shapiro-
Wilk 
test * 
BB-
test* 
  
AUC0-50 
(%*min) 
Inter-
arm 
(n=10) 
-1121 
0.91 79 10 4 0.21 0.30 
(-7490, 5249) 
Inter-
period 
(n=23) 
-848 
0.83 117 14 6 0.64 0.18 
(-3881, 2185) 
t30  Inter-
arm 
(n=10) 
-51 
0.95 40 5 3 0.0777 0.3355 
(%) (-177, 75) 
  Inter-
period 
(n=23) 
-62 
0.45 551 63 23 0.0002 0.0664   
(-313, 1878) 
 
 
Test-retest inter-period and inter-arm reproducibility data for DBF response expressed as percentage change in baseline at 30min (t30)  
and as AUC of percent change from baseline from 0 min to 50 min (AUC0-50). 
CCC: concordance correlation coefficient 
CCC>0.9, almost perfect; CCC 0.8-0.9, substantial; CCC 0.65-0.8, moderate; CCC<0.65, poor 
SSC: sample size calculation to detect an X% shift between two independent groups with an 80% power, a 5% significance level, and an active/placebo ratio of 1 
*Shapiro-Wilk test: p>0.05 indicates normal distribution of data 
**Bradley-Blackwood Test: p<0.05 indicates evidence of unequal means or unequal variances between visits or arms 
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Figure 1: Dose finding of the DBF response after vehicle ( ) and 3% ( ), 10% (  ) and 30% (
) cinnamaldehyde (CA) application , expressed as % change from baseline over time (A), and 
expressed as area under the curve (AUC) from 0-50 minutes (B), in healthy volunteers (n=11) and 
shown as LDI images in 1 healthy volunteer (C) 
(A)  and (B): * : p < 0.05 when comparing 10% to 30% CA;  **: p<0.05 when comparing 3% to 30% CA 
; p<0.001 when comparing 3%, 10%, 30% CA to vehicle (one-way ANOVA with post-hoc Bonferroni).  
N.S.: non-significance. Data expressed as mean ± 95% CI  
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Figure 2: (A) Comparison of the DBF response after 10% CA between visit 1( ) and visit 2 ( ) 
and after vehicle between visit 1 ( ) and visit 2 ( ) i.e. inter-period reproducibility (n=23). (B) 
Comparison of the DBF response after 10% CA between right ( ) and left arm ( ) and after 
vehicle between right ( ) and left ( ) arm i.e. inter-arm reproducibility (n=10).  
(A) and (B): N.S.: non-significance (p>0.05, student paired T-test to compare between arms and 
periods). Data expressed as mean ± 95% CI. 
 
